EurekAlert! InContext Modules

Public Release: 25-Oct-2012

Cell
Scientists create first mouse model of typhoid fever
Researchers have created the first true mouse model of typhoid infection. The development promises to advance the study of typhoid and the creation of new vaccines against the infection, which remains a major health threat in developing countries.

National Institutes of Health

Public Release: 25-Oct-2012

Structure
Structure discovered for promising tuberculosis drug target
Researchers at Johns Hopkins have figured out the three-dimensional shape of the protein responsible for creating unique bonds within the cell wall of the bacteria that cause tuberculosis. The bonds make the bacteria resistant to currently available drug therapies, contributing to the alarming rise of these super-bacteria throughout the world.

National Institutes of Health, NIH/National Institute of Allergy and Infectious Diseases

Public Release: 25-Oct-2012

Cell
An animal model of typhoid fever could lead to better vaccines
The first mouse model of the common bacterial disease typhoid fever is reported in a study published by Cell Press Oct. 25 in the journal Cell. Because the animals show human-like symptoms and respond positively to immunization, they could be used to develop more effective vaccines against the deadly pathogen.

Public Release: 24-Oct-2012

J of Biomedicine and Biotechnology
Plants provide accurate low-cost alternative for diagnosis of West Nile Virus
Qiang "Shawn" Chen, a researcher at Arizona State University's Biodesign Institute and a professor in the College of Technology and Innovation has developed a new method of testing for West Nile, using plants to produce biological reagents for detection and diagnosis.

Public Release: 23-Oct-2012

PLOS Medicine
Product regulatory systems in low-and middle-income countries must be strengthened
When regulatory systems for medical products in low-and middle-income countries work, people live but when such systems fail, people die, according to experts from the US Food and Drug Administration writing in this week's PLOS Medicine.

Public Release: 22-Oct-2012

Proceedings of the National Academy of Sciences
Technology brings new life to the study of diseases in old bones
A study led by The University of Manchester has demonstrated that new technology that can analyze millions of gene sequences in a matter of seconds is an effective way to quickly and accurately identify diseases in skeletons.

Public Release: 22-Oct-2012

Proceedings of the National Academy of Sciences
CU-Boulder discoveries hold promise for treatment of Hepatitis B virus
A University of Colorado Boulder-led team has discovered two prime targets of the Hepatitis B virus in liver cells, findings that could lead to treatment of liver disease in some of the 400 million people worldwide currently infected with the virus.

National Institutes of Health

Public Release: 19-Oct-2012

Journal of Biological Chemistry
Cholera discovery could revolutionize antibiotic delivery
Three Simon Fraser University scientists are among six researchers who've made a discovery that could help revolutionize antibiotic treatment of deadly bacteria. They have explained how Vibrio cholerae became a deadly pathogen thousands of years ago. Two genes within V. cholerae's genome make it toxic and deadly. The bacterium acquired these genes when a bacterial virus or bacteriophage called CTX-phi infected it. The Journal of Biological Chemistry has just published a paper written by the researchers.

Public Release: 18-Oct-2012

7th Annual AZBio Awards
TGen's and NAU's Dr. Paul Keim named AZBio's 2012 Bioscience Researcher of the Year
Dr. Paul Keim, Director of the Pathogen Genomics Division of the Translational Genomics Research Institute and the Cowden Endowed Chair of Microbiology at Northern Arizona University, will receive the 2012 Bioscience Researcher of the Year award from the Arizona BioIndustry Association.

Public Release: 18-Oct-2012

First Africa Regional Conference on Gerontology and Geriatrics
Bristol-Myers Squibb Foundation's SECURE THE FUTURE® program announces new findings confirming Grandmothers Against Poverty and AIDS has positive impact on mitigating HIV/AIDS impact in the community
Survey finds empowerment program helps 57 percent of respondents reduce socioeconomic impact of HIV/AIDS by providing tools to reduce poverty and emotional burden of disease.

Public Release: 17-Oct-2012

Journal of Medicinal Chemistry
New malaria drug requires just one dose and appears twice as effective as existing regimen
Scientists are reporting development of a new malaria drug that, in laboratory tests, has been twice as effective as the best current medicine against this global scourge and may fight off the disease with one dose, instead of the multiple doses that people often fail to take. A report on the drug appears in ACS' Journal of Medicinal Chemistry.

Public Release: 17-Oct-2012
As MDR-TB continues to spread, efforts coordinating TB detection and treatment hold promise
A new partnership announced today will increase efforts to coordinate the development of complementary novel tools to fight TB, including drug-resistant TB, and identify emerging drug resistance trends around the globe.

Public Release: 17-Oct-2012

Science Translational Medicine
Epigenetic analysis of stomach cancer finds new disease subtypes
Researchers at the Duke-NUS Graduate Medical School in Singapore have identified numerous new subtypes of gastric cancer that are triggered by environmental factors.

Public Release: 16-Oct-2012
UNC-led consortium awarded $4 million to train next generation of global health researchers
The University of North Carolina at Chapel Hill is leading a consortium that will help cultivate the next generation of global health clinicians and scientists, offering a 10-month training fellowship at one of 17 sites in 13 countries in Asia, Africa, and South America.

NIH/Fogarty International Center

Public Release: 16-Oct-2012

Biophysical Journal
Novel insights into the physical basis of sickle cell disease could lead to better treatments
Sickle cell disease -- the most common inherited blood disorder in the United States -- causes red blood cells to distort into a crescent shape and block small blood vessels. New insights into how these abnormal cells disrupt circulation could lead to more effective treatment strategies, as revealed by a study published by Cell Press in the Oct. 17 issue of Biophysical Journal.

Public Release: 15-Oct-2012

Proceedings of the National Academy of Sciences
Ebola antibody treatment, produced in plants, protects monkeys from lethal disease
A new Ebola virus study resulting from a widespread scientific collaboration has shown promising preliminary results, preventing disease in infected nonhuman primates using monoclonal antibodies. When treatment was administered one hour after infection, all animals survived. Two-thirds of the animals were protected even when the treatment, known as MB-003, was administered 48 hours after infection.

National Institutes of Health, Defense Advanced Research Projects Agency, Transformational Medical Technologies Initiative, Defense Threat Reduction Agency

Public Release: 15-Oct-2012
Urgent need for tuberculosis vaccines; experts report progress, obstacles in growing drug resistance
Drawing on recent findings of a significant rise in cases of drug-resistant tuberculosis in the UK and globally, top TB researchers at a briefing today in London called for greater focus on the quest for new vaccines--a crucial long-term, cost-effective method for addressing the growing threat.

Public Release: 11-Oct-2012

Science
Using cell phone data to curb the spread of malaria
New research that combines cell phone data from 15 million people in Kenya with detailed information on the regional incidence of malaria has revealed how human travel patterns contribute to the disease's spread.

NIH Models of Infectious Disease Agent Study Program, National Science Foundation

Public Release: 10-Oct-2012
Aeras signs agreement with GSK to jointly advance TB vaccine
Aeras announces that it has signed an agreement with GlaxoSmithKline Vaccines, S.A. (GSK) to jointly advance the clinical development of an investigational tuberculosis (TB) vaccine containing GSK's proprietary M72 antigen and AS01E* adjuvant. This novel research and resource-sharing agreement between the largest non-profit TB vaccine biotech and one of the world's leading research-based pharmaceutical and healthcare companies marks advancement in the race to develop new vaccines against TB, a global infectious disease killer.

Public Release: 10-Oct-2012
How to address mental disorders in developing countries, 'the most neglected of neglected diseases'
Canadian funding of $19.4 million will support 15 landmark projects to improve mental health diagnosis and care in developing countries: "the most neglected of neglected diseases." Many projects address problems in nations ravaged by conflict and disaster as well as poverty. Of almost 450 million people with mental health disorders, over 75% live in developing countries. WHO estimates 85% of those with serious mental disorders in the developing world receive no treatment at all.

Public Release: 9-Oct-2012

PLOS Medicine
Most pregnancy-related infections are caused by 4 treatable conditions
In low-and-middle income countries, pregnancy-related infections are a major cause of maternal death, can also be fatal to unborn and newborn babies, and are mostly caused by four types of conditions that are treatable and preventable, according to a review by US researchers published in this week's PLOS Medicine.

Public Release: 8-Oct-2012

Emerging Infectious Diseases
MRSA researchers identify new class of drug effective against superbug
In two separate published studies, researchers at The Ohio State University Wexner Medical Center have discovered a new class of treatment against methicillin-resistant Staphylococcus aureus as well as evidence of a growing need to quickly genotype individual strains of the organism most commonly referred to as the "superbug."

NIH/National Center for Advancing Translational Sciences

Public Release: 5-Oct-2012
Johns Hopkins Bloomberg School of Public Health awards Dean's Medal to William Foege
Michael J. Klag, M.D., M.P.H., dean of the Johns Hopkins Bloomberg School of Public Health, has awarded the Dean's Medal -- the School's highest honor -- to William Foege, M.D., M.P.H.

Johns Hopkins Bloomberg School of Public Health

Public Release: 3-Oct-2012

American Journal of Tropical Medicine and Hygiene
Chloroquine makes comeback to combat malaria
Malaria-drug monitoring over the past 30 years has shown that malaria parasites develop resistance to medicine, and the first signs of resistance to the newest drugs have just been observed. At the same time, resistance monitoring at the University of Copenhagen shows that the previously efficacious drug chloroquine is once again beginning to work against malaria. In time that will ensure cheaper treatment for the world's poor.

Public Release: 2-Oct-2012

Langmuir
Sticky paper offers cheap, easy solution for paper-based diagnostics
Global health researchers are working on cheap systems like a home-based pregnancy test that might work for malaria, diabetes or other diseases. A new chemical technique makes medically interesting molecules stick to regular paper -- a possible route to building such paper-based diagnostics from paper you could buy at an office-supply store.

Washington Research Foundation, University of Washington's Royalty Research Fund


			HOME DISCLAIMER PRIVACY POLICY TERMS & CONDITIONS CONTACT US TOP Copyright ©2012 by AAAS, the science society.